According to the current analysis of Reports and Data, the global Hemophilia B Market was valued at USD 12.41 Billion in 2020 and is expected to reach USD 18.75 Billion by the year 2028, at a CAGR of 5.20%. Hemophilia B is a rare genetic disorder in which blood doesn't clot normally because it lacks sufficient blood-clotting proteins known as clotting factors. Among the types of disorders, type A is anticipated to be multiple times more predominant than type B.  The global market for Hemophilia B drugs is growing significantly, owing to the increasing number of hemophilic patients globally. Hemophilia B medications are turning out to be one of the essential medicinal products to confine the loss of blood as there is no exact treatment accessible to treat this disorder. Strategies such as geographical expansion by the key market players and new product development are expected to have the most impact on the Hemophilia B market.  Rising prevalence of the disorder, a significant focus of key market players on the development of gene therapy mechanism,  increasing awareness about the disorder, and favorable regulatory scenario, are some of the key factors that support the market growth in the industry.

However, lack of availability of medicine and high cost of treatment are the factors that limit the market growth over the globe during 2019-2027.

Request a sample Report of Hemophilia B Market Market @ https://www.reportsanddata.com/sample-enquiry-form/2249

Further key findings from the report suggest

  • Launch of products for Hemophilia B treatment is expected to support the market growth during the coming years. For instance, in May 2019 FDA approved Roche’s Hemlibra for treatment of Hemophilia B with or without inhibitors.
  • North America dominates the regional Hemophilia B market and held around 48% market share in 2019.
  • Hemophilia B B is projected to be the fastest growing segment at a CAGR of 5.7%. However, low availability of treatment for the segment is a major challenge for the market growth for this segment.
  • Asia Pacific is expected to show a high growth rate in the hemophilic market and will grow at a CAGR of 6%
  • Recombinant coagulation factor concentrate and plasma coagulation factor concentrate are the common options to treat Hemophilia B and are expected to take up an important position in the global Hemophilia B market owing to increased prevalence of the von Willebrand Disease.
  • On-demand treatment segment is expected to grow at a CAGR of 5.6%.
  • Treatment for Hemophilia B is in the clinical pipeline stage. And the multiple treatments that are underway are expected to significantly improve the quality of life of patients suffering from Hemophilia B.
  • Availability of treatment and lack of awareness about Hemophilia B is likely to hinder the market growth during the forecast period.

Key Players covered in this report are

Shire (Takeda), Bayer Healthcare, CSL Behring, Novo Nordisk, Sanofi, Pfizer Inc., among others.

Type (Revenue, USD Million; 2018–2028)

  • Hemophilia B A
  • Hemophilia B B
  • Hemophilia B C
  • Others

Product (Revenue, USD Million; 2018–2028)

  • Plasma derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Factor XII
    • Activated prothrombin complex concentrate
    • Von Willebrand factor
  • Recombinant coagulation factor concentrates           
    • Factor VIII
    • Factor IX
    • Von Willebrand factor
  • Desmopressin
  • Antifibrinolytic agents
  • Others

Treatment Type (Revenue, USD Million; 2018–2028)

  • Prophylactic
  • On-Demand

Therapy Type (Revenue, USD Million; 2018–2028)

  • Replacement Therapy
  • Immune Tolerance Induction Therapy
  • Gene Therapy

 

Based on Region market is segmented into:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

 

Major Points covered in this report are as below:

  • An analysis of Hemophilia B Market industry development trends and marketing channels, as well as an assessment of the feasibility of new investment projects, is presented in the study.

 

  • In addition to providing key statistics on the industry, the report provides valuable guidance and direction for companies and individuals interested in this market through tables and figures.

 

  • In addition to developing policies and plans, this report analyzes manufacturing processes and cost structures. It also provides information about import/export demand, costs, prices, revenues, and gross margins.

 

  • This report provides information on the market status of Hemophilia B Market manufacturers and provides valuable insight into the market for companies and individuals.


We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa

 

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2249

 

Thank you for reading the report. Kindly note that we also offer customized reports according to the client's requirements. Contact us to know more about the customization feature and our team will provide you with the best-customized report

 

Explore More Industry Research by Reports and Data:

Chiropractic Market @ https://www.biospace.com/article/chiropractic-market-size-share-and-industry-analysis-by-product-type-by-end-use-and-forecast-to-2028/

Endotracheal Tube Market @ https://www.biospace.com/article/endotracheal-tube-market-size-share-industry-analysis-by-product-type-by-route-type-by-application-by-end-use-and-by-regional-forecast-to-2028/

Reverse Transcriptase Market @ https://www.biospace.com/article/reverse-transcriptase-market-size-share-and-industry-analysis-by-product-type-by-application-by-sales-channel-and-by-regional-forecast-to-2028/

Surgical Devices Market @ https://www.biospace.com/article/surgical-devices-market-size-to-reach-usd-20-20-billion-in-2028-says-reports-and-data-/

 

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

 

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs